NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Languages English Remove constraint Languages: English Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

5221. Recommendations for dual 510(k) and CLIA waiver by application studies: guidance for industry and Food and Drug Administration staff

5229. Slowly progressive, low-prevalence rare diseases with substrate deposition that result from single enzyme defects: providing evidence of effectiveness for replacement or corrective therapies